Assessment of Novel Technologies in Healthcare - Off-label Use of Drugs and the Ethics of Implementation and Distribution of COVID-19 Vaccines

Overview

Journal Einstein (Sao Paulo)

Specialty General Medicine

Date 2022 Jan 12

PMID 35019043

Authors

Vivian Iida Avelino-Silva

Mario Thadeu Leme de Barros Filho

Affiliations

Soon will be listed here.

Citing Articles

Development of a mobile application for health education about sepsis.

Limeira J, Silva V, Galindo Neto N, Dias Torres Silva C, Oliveira V, Alexandre A Rev Esc Enferm USP. 2023; 57:e20220269.

PMID: 37285575 PMC: 10263185. DOI: 10.1590/1980-220X-REEUSP-2022-0269en.

References

Sze S, Pan D, Nevill C, Gray L, Martin C, Nazareth J . Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2020; 29:100630. PMC: 7658622. DOI: 10.1016/j.eclinm.2020.100630. View

Siedner M, Alba C, Fitzmaurice K, Gilbert R, Scott J, Shebl F . Cost-effectiveness of Coronavirus Disease 2019 Vaccination in Low- and Middle-Income Countries. J Infect Dis. 2022; 226(11):1887-1896. PMC: 9214172. DOI: 10.1093/infdis/jiac243. View

Self W, Semler M, Leither L, Casey J, Angus D, Brower R . Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(21):2165-2176. PMC: 7653542. DOI: 10.1001/jama.2020.22240. View

Gur-Arie R, Jamrozik E, Kingori P . No Jab, No Job? Ethical Issues in Mandatory COVID-19 Vaccination of Healthcare Personnel. BMJ Glob Health. 2021; 6(2). PMC: 7893205. DOI: 10.1136/bmjgh-2020-004877. View

Kalil A . Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA. 2020; 323(19):1897-1898. DOI: 10.1001/jama.2020.4742. View

Afshinnekoo E, Bhattacharya C, Burguete-Garcia A, Castro-Nallar E, Deng Y, Desnues C . COVID-19 drug practices risk antimicrobial resistance evolution. Lancet Microbe. 2021; 2(4):e135-e136. PMC: 7906697. DOI: 10.1016/S2666-5247(21)00039-2. View

Logunov D, Dolzhikova I, Shcheblyakov D, Tukhvatulin A, Zubkova O, Dzharullaeva A . Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021; 397(10275):671-681. PMC: 7852454. DOI: 10.1016/S0140-6736(21)00234-8. View

Vasileiou E, Simpson C, Shi T, Kerr S, Agrawal U, Akbari A . Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021; 397(10285):1646-1657. PMC: 8064669. DOI: 10.1016/S0140-6736(21)00677-2. View

Wouters O, Shadlen K, Salcher-Konrad M, Pollard A, Larson H, Teerawattananon Y . Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet. 2021; 397(10278):1023-1034. PMC: 7906643. DOI: 10.1016/S0140-6736(21)00306-8. View

10.

Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C . A global database of COVID-19 vaccinations. Nat Hum Behav. 2021; 5(7):947-953. DOI: 10.1038/s41562-021-01122-8. View

11.

Alpern J, Gertner E . Off-Label Therapies for COVID-19-Are We All In This Together?. Clin Pharmacol Ther. 2020; 108(2):182-184. PMC: 7264670. DOI: 10.1002/cpt.1862. View

12.

Graeber D, Schmidt-Petri C, Schroder C . Attitudes on voluntary and mandatory vaccination against COVID-19: Evidence from Germany. PLoS One. 2021; 16(5):e0248372. PMC: 8109805. DOI: 10.1371/journal.pone.0248372. View

13.

Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K . Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2020; 21(2):181-192. PMC: 7832443. DOI: 10.1016/S1473-3099(20)30843-4. View

14.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021; 397(10277):881-891. PMC: 7894131. DOI: 10.1016/S0140-6736(21)00432-3. View

15.

Paumgartten F, Oliveira A . Off label, compassionate and irrational use of medicines in Covid-19 pandemic, health consequences and ethical issues. Cien Saude Colet. 2020; 25(9):3413-3419. DOI: 10.1590/1413-81232020259.16792020. View

16.

. [Off label use: a mistake or a need?]. Rev Saude Publica. 2012; 46(2):398-9. DOI: 10.1590/s0034-89102012000200026. View

17.

Aliberti M, Szlejf C, Avelino-Silva V, Suemoto C, Apolinario D, Dias M . COVID-19 is not over and age is not enough: Using frailty for prognostication in hospitalized patients. J Am Geriatr Soc. 2021; 69(5):1116-1127. PMC: 8251205. DOI: 10.1111/jgs.17146. View

18.

Beyzarov E, Chen Y, Julg R, Naim K, Shah J, Gregory W . Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective. Drug Saf. 2020; 44(1):95-105. PMC: 7755229. DOI: 10.1007/s40264-020-01035-x. View

19.

Tenforde M, Olson S, Self W, Talbot H, Lindsell C, Steingrub J . Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(18):674-679. PMC: 9368749. DOI: 10.15585/mmwr.mm7018e1. View

20.

Khan M, Ali S, Adelaine A, Karan A . Rethinking vaccine hesitancy among minority groups. Lancet. 2021; 397(10288):1863-1865. PMC: 8059987. DOI: 10.1016/S0140-6736(21)00938-7. View